Advertisement
Australia markets open in 1 hour 55 minutes

  • ALL ORDS

    7,831.90
    -100.10 (-1.26%)
     

  • AUD/USD

    0.6532
    +0.0053 (+0.81%)
     

  • ASX 200

    7,569.90
    -94.20 (-1.23%)
     

  • OIL

    79.13
    +0.13 (+0.16%)
     

  • GOLD

    2,330.20
    +19.20 (+0.83%)
     

  • Bitcoin AUD

    88,787.73
    -3,370.02 (-3.66%)
     

  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     

BridgeBio Pharma (BBIO) Dips More Than Broader Markets: What You Should Know

Zacks Equity Research
·2-min read

BridgeBio Pharma (BBIO) closed at $14.65 in the latest trading session, marking a -1.81% move from the prior day. This change lagged the S&P 500's daily loss of 0.41%. Meanwhile, the Dow lost 0.01%, and the Nasdaq, a tech-heavy index, added 0.13%.

Prior to today's trading, shares of the rare disease drug developer had lost 59.91% over the past month. This has lagged the Medical sector's loss of 0.21% and the S&P 500's gain of 2.36% in that time.

Investors will be hoping for strength from BridgeBio Pharma as it approaches its next earnings release. The company is expected to report EPS of -$0.80, up 20.79% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $33.19 million, up 27561.67% from the year-ago period.

Investors should also note any recent changes to analyst estimates for BridgeBio Pharma. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

ADVERTISEMENT

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.72% lower. BridgeBio Pharma is currently sporting a Zacks Rank of #3 (Hold).

The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 58, putting it in the top 23% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BridgeBio Pharma, Inc. (BBIO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research